
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc demonstrated strong financial performance with a 21% increase in top-line growth during Q3, driven by a 13% rise in volumes and a 5% lift in average selling prices. The company achieved its highest cash collections in October and reported positive GAAP net income while raising both top and bottom line guidance, reflecting an optimistic outlook. Furthermore, with a recent 50% expansion of its sales force, CareDx is positioned for sustained volume growth moving forward, particularly following a solid 19% year-over-year increase in kidney surveillance volumes recorded earlier in the year.
Bears say
CareDx Inc reported Q3'25 test volumes of 50,000, which, despite a year-over-year increase of 13%, fell short of expectations, indicating potential stagnation, particularly in the autumn months. The company's shares have faced significant pressure, trading at 1.4 times projected revenue for 2026, which is substantially below historical averages and other diagnostic peers. Additionally, CareDx is grappling with concerns regarding its ability to successfully commercialize new diagnostic solutions, compounded by ongoing management turnover that may further hinder its growth strategy.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares